Dr. Jinbo Yue 岳金波
Chief Physician, Associate Professor
Department of Thoracic Radiation Oncology I, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy for liver cancer, intrahepatic cholangiocarcinoma, gastric cancer, pancreatic cancer, urologic cancers (prostate, kidney), lymphoma, and skin and soft tissue tumors.
Dr. Yue is a Chief Physician and Associate Professor with a doctorate in radiation oncology. With 18 years of clinical experience, Dr. Yue was a visiting scholar at Duke University (2009–2010) and M.D. Anderson Cancer Center (2014–2016). Dr. Yue serves as Deputy Director of the First Radiation Therapy Department and contributed to the 2018 expert consensus on multidisciplinary treatment of colorectal cancer lung metastases.
Professional roles
- Member, Chinese Medical Association
- Vice Chair, Radiotherapy Group of Liver Cancer Professional Committee, China Anti-Cancer Association
- Vice Chair, Radiation Oncology Branch, China Medicine Education Association
- Editorial Board Member, Radiation Oncology
Name order: in Chinese the family name comes first (Yue Jinbo). Papers usually list the name as Jinbo Yue or Yue J.
Selected publications
115 papers on PubMed matched by name and affiliation; 59 as first or senior author since 2016. Most recent first- or senior-author papers:
- Radiother Oncol, 2026 (senior author): Radiotherapy for female non-gynecologic pelvic and adjacent cancers and secondary uterine Cancers: a SEER analysis. PubMed 42471142
- Int J Radiat Oncol Biol Phys, 2026 (senior author): Sleep Adjustment Strategy for Reducing Sedation Use in Pediatric Radiotherapy Under Surface Optical Monitoring: A Pragmatic Randomized Feasibility Trial. PubMed 42526653
- Ther Adv Med Oncol, 2026 (senior author): Bevacizumab plus iparomlimab/tuvonralimab with hepatic artery infusion chemotherapy followed by stereotactic body radiotherapy in patients with BCLC stage C hepatocellular carcinoma with thrombus and/or extrahepatic oligometastases (BITS-TO-HCC): study protocol of a prospective, single-center, single-arm, phase II study. PubMed 42502358
- Clin Cancer Res, 2026 (senior author): Continuation of First-Line Systemic Therapy with Progression-Directed Radiotherapy in Patients with Oligoprogressive Hepatocellular Carcinoma: A Multicenter, Single-Arm, Phase II Trial. PubMed 42126314
- BMJ Open, 2026 (senior author): Continuation of first-line therapy with radiotherapy for oligoprogression versus early switch to second-line therapy in oligoprogressive hepatocellular carcinoma (CROSS): study protocol of a multicentre, randomised, controlled, open-label, phase III trial. PubMed 42264528
- Crit Rev Oncol Hematol, 2026 (senior author): Proton beam therapy versus photon therapy for multiple malignancies: An umbrella systematic review and meta-analysis. PubMed 41831626
- Front Immunol, 2026 (senior author): Sintilimab plus fruquintinib with or without radiotherapy for third-line treatment of colorectal cancer with liver metastases: study protocol for a randomized controlled, multicenter phase II trial. PubMed 42206059
- Clin Exp Med, 2026 (senior author): Dynamic changes in gut microbiota and discovery of prognostic biomarkers in locally advanced pancreatic cancer during chemoradiotherapy. PubMed 42071032
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion